MANUFACTURING AND OPTION AGREEMENT BY AND BETWEEN INTERNATIONAL WEX TECHNOLOGIES INC. AND SABEX 2002 INC.Manufacturing Agreement • June 9th, 2009 • Wex Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances • Quebec
WHEREAS WEX is a biopharmaceutical research and development corporation actively involved in the field of neurobioscience with its core business being the research and development of innovative pharmaceutical compounds for use in the treatment of drug addiction, pain management and anaesthesia;
PRIVATE PLACEMENT SUBSCRIPTION AMENDING AGREEMENTPrivate Placement Subscription Agreement • June 9th, 2009 • Wex Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances • British Columbia
WEX PHARMACEUTICALS INC. (formerly known as INTERNATIONAL WEX TECHNOLOGIES INC.), a corporation formed under the Canada Business Corporations Act and having an office at 2100 – 1040 West Georgia Street, Vancouver, British Columbia V6E 4H1
COLLABORATION TERMINATION AGREEMENTCollaboration Termination Agreement • June 9th, 2009 • Wex Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances
PRIVATE PLACEMENT SUBSCRIPTION AGREEMENTPrivate Placement Subscription Agreement • June 9th, 2009 • Wex Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances • British Columbia
DEBENTURE AMENDMENT AGREEMENTDebenture Amendment Agreement • June 9th, 2009 • Wex Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances
WEX PHARMACEUTICALS INC. (formerly known as INTERNATIONAL WEX TECHNOLOGIES INC.), a corporation formed under the Canada Business Corporations Act and having an office at 2100 – 1040 West Georgia Street, Vancouver, British Columbia V6E 4H1
SUBSCRIPTION AGREEMENTSubscription Agreement • June 9th, 2009 • Wex Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances • British Columbia
The undersigned (the “Subscriber”) hereby agrees to purchase from the Corporation 16,327.272 common shares (the “Offered Shares”) of the Corporation for aggregate consideration of $4,489,999.80 (the “Subscription Price”), representing a subscription price of $0.275 per Offered Share and agrees to advance to the Corporation Cdn$l5,600,000 (the “Debenture Proceeds”) for a convertible debenture in the principal amount of Cdn$15,600,000 in the form attached as Schedule “A” (the “Convertible Debenture”), such advance to be in accordance with the terms of the Convertible Debenture, which Convertible Debenture will be convertible into common shares of the Corporation and pay interest by the issuance of common shares of the Corporation in accordance with the terms of the Convertible Debenture (together the “Debenture Shares” and together with the Convertible Debenture and the Offered Shares the “Securities”) on the terms and conditions set out in this subscription agreement (the “Subscription
